C. Porter

Christine M. Madla, L. Marciani, D. V. van Riet-Nales, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers.

J. Quinn, Jinming Hu, T. P. Davis, 2015, Nanomedicine : nanotechnology, biology, and medicine.

Size and rigidity of cylindrical polymer brushes dictate long circulating properties in vivo.

F. Caruso, B. Boyd, C. Porter, 2015, ACS nano.

Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating.

S. Davis, C. Porter, L. Illum, 1991, Biochemical and biophysical research communications.

Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow

M. Davies, S. Davis, S. Moghimi, 1992 .

A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.

Ben J Boyd, Christopher J H Porter, Lisa M Kaminskas, 2012, Nanomedicine : nanotechnology, biology, and medicine.

Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation.

L. Kaminskas, Victoria M Mcleod, B. Boyd, 2012, Molecular pharmaceutics.

years of oral lipid-based formulations : Provenance , progress and future perspectives ☆

Christopher J. H. Porter, Colin W. Pouton, Christel A. S. Bergström, 2016 .

Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport

C. Porter, N. Trevaskis, T. Quach, 2022, Frontiers in Pharmacology.

An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.

C. Pouton, C. Porter, H. Williams, 2014, Molecular pharmaceutics.

Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases.

C. Prestidge, Katharina Richter, B. Boyd, 2015, Molecular pharmaceutics.

Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.

G. Edwards, C. Prestidge, B. Boyd, 2013, Journal of controlled release : official journal of the Controlled Release Society.

A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.

B. Boyd, C. Porter, S. Khoo, 2007, International journal of pharmaceutics.

Lymphatic transport of proteins after subcutaneous administration.

C. Porter, S. Charman, 2000, Journal of pharmaceutical sciences.

Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations

A. Müllertz, C. Pouton, C. Porter, 2013, Pharmaceutical Research.

Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug.

C. Porter, N. Trevaskis, T. Quach, 2016, Journal of pharmaceutical sciences.

The impact of lymphatic transport on the systemic disposition of lipophilic drugs.

C. Porter, N. Trevaskis, J. Bulitta, 2013, Journal of pharmaceutical sciences.

A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport

P. Tso, C. Porter, W. Charman, 2013, Pharmaceutical Research.

A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions.

C. Porter, M. Scanlon, W. Charman, 1995, Journal of pharmaceutical and biomedical analysis.

Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.

C. Porter, S. Charman, W. Charman, 1996, Journal of pharmaceutical sciences.

Lipophilic prodrugs designed for intestinal lymphatic transport

C. Porter, W. Charman, 1996 .

Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid.

C. Porter, W. Charman, K. Wasan, 1999, Journal of pharmaceutical sciences.

Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model

C. Porter, W. Charman, M. Mcintosh, 2004, The Journal of pharmacy and pharmacology.

Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update☆

Christopher J H Porter, Natalie L Trevaskis, C. Porter, 2007, Advanced Drug Delivery Reviews.

Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice.

U. V. von Andrian, J. Mintern, C. Nowell, 2021, Journal of controlled release : official journal of the Controlled Release Society.

Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs.

G. Edwards, C. Porter, N. Trevaskis, 2016, Molecular pharmaceutics.

Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin® US2: effect of drug type and formulation composition on in vitro pharmaceutical performance.

C. Porter, P. Augustijns, H. Williams, 2014, Journal of pharmaceutical sciences.

Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.

V. Stella, C. Porter, W. Charman, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Profiling the Role of Deacylation-Reacylation in the Lymphatic Transport of a Triglyceride-Mimetic Prodrug

C. Porter, N. Trevaskis, T. Quach, 2014, Pharmaceutical Research.

Acute hypertriglyceridemia promotes intestinal lymphatic lipid and drug transport: a positive feedback mechanism in lipid and drug absorption.

C. Porter, W. Charman, N. Trevaskis, 2011, Molecular pharmaceutics.

Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat

C. Porter, W. Charman, N. Trevaskis, 2005, Pharmaceutical Research.

The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport

C. Porter, W. Charman, N. Trevaskis, 2006, Journal of Pharmacology and Experimental Therapeutics.

An Acute and Coincident Increase in FABP Expression and Lymphatic Lipid and Drug Transport Occurs During Intestinal Infusion of Lipid-Based Drug Formulations to Rats

P. Tso, C. Porter, W. Charman, 2006, Pharmaceutical Research.

Lymphatic Absorption of Orally Administered Prodrugs

David M. Shackleford, C. Porter, W. Charman, 2007 .

Lipid-based formulations: exploring the link between in vitro supersaturation and in vivo exposure

Dallas B. Warren, Colin W. Pouton, Hassan Benameur, 2011 .

Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep

Donald E Mager, Christopher J H Porter, Susan A Charman, 2004, Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic Model to Describe the Lymphatic Absorption of r-metHu-Leptin After Subcutaneous Injection to Sheep

Steven W. Martin, G. Edwards, C. Porter, 2003, Pharmaceutical Research.

Promoting intestinal lymphatic transport targets a liver‐X receptor (LXR) agonist (WAY‐252,623) to lymphocytes and enhances immunomodulation

S. Martinsson, E. Michaëlsson, C. Porter, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Structured Triglyceride Vehicles for Oral Delivery of Halofantrine: Examination of Intestinal Lymphatic Transport and Bioavailability in Conscious Rats

H. Kristensen, A. Müllertz, C. Porter, 2002, Pharmaceutical Research.

Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 6: Effects of Varying Pancreatin and Calcium Levels

A. Müllertz, C. Pouton, C. Porter, 2014, The AAPS Journal.

In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623.

G. Edwards, C. Porter, N. Trevaskis, 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis.

C. Porter, W. Charman, L. Sek, 2001, Journal of pharmaceutical and biomedical analysis.

Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.

L. Kaminskas, B. Boyd, C. Porter, 2011, Nanomedicine.

High density lipoprotein composition influences lymphatic transport after subcutaneous administration.

A. Johnston, C. Porter, N. Trevaskis, 2020, Molecular pharmaceutics.

Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability.

C. Porter, N. Trevaskis, T. Quach, 2016, Angewandte Chemie.

Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration

T. Hanley, B. Boyd, C. Porter, 2011, Drug Delivery and Translational Research.

Fatty Acid-Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells.

C. Porter, M. Scanlon, J. Nicolazzo, 2017, Journal of Pharmacy and Science.

Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas.

C. Porter, W. Charman, K. Wasan, 1999, Journal of pharmaceutical sciences.

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.

D. Owen, L. Kaminskas, B. Kelly, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals

J. Beals, C. Porter, R. Hansen, 2016, Pharmaceutical Research.

Non-linear Increases in Danazol Exposure with Dose in Older vs. Younger Beagle Dogs: The Potential Role of Differences in Bile Salt Concentration, Thermodynamic Activity, and Formulation Digestion

G. Edwards, C. Pouton, C. Porter, 2014, Pharmaceutical Research.

Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms.

P. Botti, C. Pouton, C. Porter, 2019, Advanced drug delivery reviews.

Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.

C. Porter, W. Charman, B. Johnson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.

L. Kaminskas, Victoria M Mcleod, B. Boyd, 2011, Journal of pharmaceutical sciences.

Lymphatic transport of proteins after s.c. injection: implications of animal model selection.

G. Edwards, C. Porter, S. Charman, 2001, Advanced drug delivery reviews.

PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.

L. Kaminskas, B. Kelly, Victoria M Mcleod, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Quantitatively Tracking Bio-Nano Interactions of Metal-Phenolic Nanocapsules by Mass Cytometry.

F. Caruso, S. Kent, Yi Ju, 2021, ACS applied materials & interfaces.

Dendrimers for biomedical applications

L. Kaminskas, Victoria M Mcleod, B. Boyd, 2014 .

Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.

L. Kaminskas, B. Boyd, G. Krippner, 2009, Journal of pharmaceutical sciences.

Lymphatic uptake of liposomes after intraperitoneal administration primarily occurs via the diaphragmatic lymphatics and is dependent on liposome surface properties.

J. Windsor, C. Porter, A. Phillips, 2019, Molecular pharmaceutics.

Biocompatible Cationic Lipoamino Acids as Counterions for Oral Administration of API-Ionic Liquids

C. Porter, H. Williams, H. Benameur, 2022, Pharmaceutical Research.

Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.

D. Owen, D. Ascher, T. Velkov, 2015, Molecular pharmaceutics.

Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site.

D. Owen, L. Kaminskas, B. Kelly, 2017, Nanomedicine : nanotechnology, biology, and medicine.

Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers

D. Owen, C. Pouton, L. Kaminskas, 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats.

J. Quinn, Jinming Hu, T. P. Davis, 2016, Journal of pharmaceutical sciences.

Evaluation of the structural determinants of polymeric precipitation inhibitors using solvent shift methods and principle component analysis.

Dallas B. Warren, Christel A. S. Bergström, C. Pouton, 2013, Molecular pharmaceutics.

Spatial Properties of Reactive Oxygen Species Govern Pathogen-Specific Immune System Responses

D. Brooks, C. Porter, L. O’Neill, 2020, Antioxidants & redox signaling.

Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.

D. Owen, L. Kaminskas, B. Kelly, 2013, Molecular pharmaceutics.

Polymeric Nanotubes as Drug Delivery Vectors—Comparison of Covalently and Supramolecularly Assembled Constructs

S. Perrier, C. Pouton, C. Porter, 2022, Biomacromolecules.

Fatty Acid-Binding Protein 5 at the Blood–Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function

P. Marriott, C. Porter, M. Scanlon, 2016, The Journal of Neuroscience.

Fatty Acid Binding Proteins: Potential Chaperones of Cytosolic Drug Transport in the Enterocyte?

C. Porter, M. Scanlon, N. Trevaskis, 2011, Pharmaceutical Research.

Population Pharmacokinetics of Colistin Methanesulfonate in Rats: Achieving Sustained Lung Concentrations of Colistin for Targeting Respiratory Infections

J. Li, R. Nation, C. Porter, 2013, Antimicrobial Agents and Chemotherapy.

Lymphatic Absorption Is a Significant Contributor to the Subcutaneous Bioavailability of Insulin in a Sheep Model

G. Edwards, C. Porter, S. Charman, 2001, Pharmaceutical Research.

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

S. Lewin, J. O’Leary, C. Sobey, 2017, Nature Communications.

Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.

L. Kaminskas, Victoria M Mcleod, C. Porter, 2015, Journal of pharmaceutical sciences.

Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker.

D. Owen, L. Kaminskas, B. Kelly, 2018, Molecular pharmaceutics.

Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.

D. Owen, L. Kaminskas, B. Kelly, 2011, Molecular pharmaceutics.

Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion.

Woldeamanuel A. Birru, Dallas B. Warren, C. Pouton, 2017, Molecular pharmaceutics.

Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation.

N. Davies, C. Berkland, L. Kaminskas, 2016, Molecular pharmaceutics.

Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies to target a model immunomodulator to the lymphatic system

V. Stella, C. Porter, W. Charman, 2013 .

Desbutylhalofantrine: Evaluation of QT Prolongation and Other Cardiovascular Effects after Intravenous Administration In Vivo

C. Porter, W. Charman, M. Mcintosh, 2003, Journal of cardiovascular pharmacology.

Fatty Acid Binding Proteins Expressed at the Human Blood–Brain Barrier Bind Drugs in an Isoform-Specific Manner

C. Porter, M. Scanlon, J. Nicolazzo, 2015, Pharmaceutical Research.

Fatty Acid-Binding Protein 5 Facilitates the Blood-Brain Barrier Transport of Docosahexaenoic Acid.

Yui Yamamoto, C. Porter, M. Scanlon, 2015, Molecular pharmaceutics.

Removal of Interstitial Hyaluronan with Recombinant Human Hyaluronidase Improves the Systemic and Lymphatic Uptake of Cetuximab in Rats.

C. Porter, M. Mcintosh, Tri-Hung Nguyen, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.

L. Kaminskas, B. Boyd, G. Krippner, 2007, Molecular pharmaceutics.

Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.

C. Pouton, C. Porter, H. Williams, 2018, Journal of Pharmacy and Science.

Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies.

C. Porter, H. Williams, P. Scammells, 2017, Molecular pharmaceutics.

Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution.

F. Caruso, S. Alcântara, S. Kent, 2017, ACS applied materials & interfaces.

Synthesis and evaluation of 5′ alkyl ester prodrugs of zidovudine for directed lymphatic delivery

C. Porter, S. Charman, W. Charman, 1996 .

Lymphatic Absorption Is the Primary Contributor to the Systemic Availability of Epoetin Alfa following Subcutaneous Administration to Sheep

Steven W. Martin, G. Edwards, C. Porter, 2005, Journal of Pharmacology and Experimental Therapeutics.

Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids.

Dallas B. Warren, C. Pouton, D. Chalmers, 2017, Molecular pharmaceutics.

Effect of dietary fatty acids on the intestinal permeability of marker drug compounds in excised rat jejunum

P. Gibson, C. Porter, S. Charman, 2002, The Journal of pharmacy and pharmacology.

Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained‐release oral drug delivery systems for poorly water‐soluble drugs II. In‐vivo evaluation

I. Larson, T. Hanley, B. Boyd, 2010 .

An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.

L. Kaminskas, Victoria M Mcleod, C. Porter, 2017, Biomacromolecules.

An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in‐vitro intestinal permeability of drug compounds of varying lipophilicity

C. Porter, S. Charman, K. Katneni, 2008 .

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals

J. M. Beals, J. Beals, C. Porter, 2016, Pharmaceutical Research.

The Absorption of Darbepoetin Alfa Occurs Predominantly via the Lymphatics Following Subcutaneous Administration to Sheep

Steven W. Martin, G. Edwards, C. Porter, 2006, Pharmaceutical Research.

Lipid-based Systems, Drug Exposure and Lead Optimization

C. Porter, S. Charman, W. Charman, 2006 .

Drug delivery to the lymphatic system.

C. Porter, 1997, Critical reviews in therapeutic drug carrier systems.

Differences in pre- and post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma.

C. Porter, W. Charman, S. Caliph, 1997, Journal of pharmaceutical and biomedical analysis.

Organ-specific lymphatics play distinct roles in regulating HDL trafficking and composition.

A. Johnston, C. Porter, N. Trevaskis, 2020, American journal of physiology. Gastrointestinal and liver physiology.

Correction to "targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?".

C. Porter, W. Charman, N. Trevaskis, 2011, Molecular pharmaceutics.

Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?

C. Porter, W. Charman, N. Trevaskis, 2010, Molecular pharmaceutics.

The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs.

C. Porter, N. Trevaskis, Yan Yan Yeap, 2013, Molecular pharmaceutics.

Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained‐release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically‐relevant media

I. Larson, T. Hanley, B. Boyd, 2010 .

A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs.

B. Boyd, C. Porter, W. Charman, 2004, Journal of controlled release : official journal of the Controlled Release Society.

Subcutaneous administration of AZD0466, a dendrimer-based Bcl-2/Bcl-xL inhibitor increases lymphatic exposure and survival in B-cell lymphoma.

A. Johnston, C. Porter, L. Kingston, 2022, Journal of Controlled Release.

Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media.

I. Larson, T. Hanley, B. Boyd, 2010, The Journal of pharmacy and pharmacology.

Strategies to Address Low Drug Solubility in Discovery and Development

Hywel D Williams, Christopher J H Porter, Colin W Pouton, 2013, Pharmacological Reviews.

Tools for Early Prediction of Drug Loading in Lipid-Based Formulations

Christopher J. H. Porter, Christel A. S. Bergström, Linda C. Alskär, 2015, Molecular pharmaceutics.

Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.

Anette Müllertz, Hywel D Williams, Philip Sassene, 2014, Journal of pharmaceutical sciences.

Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.

Christopher J H Porter, Colin W Pouton, C. Pouton, 2008, Advanced drug delivery reviews.

In vitro assessment of oral lipid based formulations.

C. Porter, W. Charman, C J Porter, 2001, Advanced drug delivery reviews.

Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach.

Ben J Boyd, Christopher J H Porter, B. Boyd, 2004, Journal of pharmaceutical sciences.

Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine

G. Edwards, C. Porter, W. Charman, 1998 .

Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components.

Woldeamanuel A. Birru, Dallas B. Warren, C. Pouton, 2014, Molecular pharmaceutics.

Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.

Hywel D Williams, Christopher J H Porter, Susan A Charman, 2015, Molecular pharmaceutics.

API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility

C. Porter, H. Williams, H. Benameur, 2020, RSC advances.

The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment.

C. Porter, W. Charman, S. Khoo, 2000, International journal of pharmaceutics.

Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.

J. Dressman, C. Porter, W. Charman, 1997, Journal of pharmaceutical sciences.

Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations

Ben J. Boyd, Christopher J. H. Porter, Ann Marie Kaukonen, 2004, Pharmaceutical Research.

Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model

G. Edwards, C. Porter, S. Charman, 2007, Drug Metabolism and Disposition.

Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation

Ben J. Boyd, Christopher J. H. Porter, Ann Marie Kaukonen, 2004, Pharmaceutical Research.

Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides.

G. Edwards, H. Kristensen, A. Müllertz, 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs

David M. Shackleford, Christopher J H Porter, G. Edwards, 2003, Journal of Pharmacology and Experimental Therapeutics.

'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.

C. Pouton, C. Porter, H. Williams, 2014, Journal of Controlled Release.

Evaluation of the in‐vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products

Christopher J H Porter, Ann Marie Kaukonen, C. Porter, 2002, The Journal of pharmacy and pharmacology.

Evaluation of emulsifiable glasses for the oral administration of cyclosporin in beagle dogs

Rachel Williams, Susan A. Charman, Rachel L. Williams, 1996 .

Computational prediction of formulation strategies for beyond-rule-of-5 compounds.

Christopher J. H. Porter, Christel A. S. Bergström, William N. Charman, 2016, Advanced drug delivery reviews.

Computational Prediction of Drug Solubility in Lipid Based Formulation Excipients

Christel A. S. Bergström, C. Porter, W. Charman, 2013, Pharmaceutical Research.

Intestinal lymphatic drug transport: an update.

C. Porter, W. Charman, C J Porter, 2001, Advanced drug delivery reviews.

Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats.

C. Porter, W. Charman, C J Porter, 2000, Journal of pharmaceutical sciences.

Targeting the lymphatics using dendritic polymers (dendrimers).

Christopher J H Porter, Lisa M Kaminskas, C. Porter, 2011, Advanced drug delivery reviews.

Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.

C. Porter, Tri-Hung Nguyen, Estelle J A Suys, 2021, Molecular pharmaceutics.

A Nonionic Polyethylene Oxide (PEO) Surfactant Model: Experimental and Molecular Dynamics Studies of Kolliphor EL.

Dallas B. Warren, C. Pouton, C. Nowell, 2019, Journal of pharmaceutical sciences.

Lymph-directed immunotherapy - Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer.

C. Porter, N. Trevaskis, O. Feeney, 2020, Advanced drug delivery reviews.

The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats.

C. Porter, J. Nicolazzo, M. Mcintosh, 2014, Molecular pharmaceutics.

Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection.

G. Edwards, C. Porter, S. Charman, 2000, Journal of pharmaceutical sciences.

Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief

Pierangelo Geppetti, Martin J. Scanlon, Christopher J. H. Porter, 2017, Science Translational Medicine.

Pointing in the Right Direction: Controlling the Orientation of Proteins on Nanoparticles Improves Targeting Efficiency.

A. Johnston, C. Porter, Moore Chen, 2019, Nano letters.

Use of plasma proteins as solubilizing agents in in vitro permeability experiments: correction for unbound drug concentration using the reciprocal permeability approach.

C. Porter, S. Charman, K. Katneni, 2008, Journal of pharmaceutical sciences.

Low Dose Lipid Formulations: Effects on Gastric Emptying and Biliary Secretion

Clive G. Wilson, Christopher J. H. Porter, C. Porter, 2007, Pharmaceutical Research.

Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles

C. Porter, N. Trevaskis, T. Quach, 2021, Pharmaceutical Research.

A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.

C. Porter, W. Charman, C J Porter, 1996, Journal of pharmaceutical sciences.

A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations

Christopher J. H. Porter, Colin W. Pouton, C. Pouton, 2015, Pharmaceutical Research.

Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network.

Clive G. Wilson, B. Griffin, P. Artursson, 2021, Advanced drug delivery reviews.

Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans

J. Windsor, C. Porter, A. Phillips, 2020, Frontiers in Physiology.

Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport.

C. Prestidge, C. Porter, N. Trevaskis, 2021, Journal of controlled release : official journal of the Controlled Release Society.

Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity

J. Windsor, C. Nowell, C. Porter, 2021, Nature Metabolism.

Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat.

J. Windsor, C. Porter, A. Phillips, 2021, International journal of pharmaceutics.

The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) and Evaluation of Their Impact on Lymph Lipoprotein Profiles

Christopher J. H. Porter, R. Shanker, C. Porter, 2010, Pharmaceutical Research.

The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623)

G. Edwards, C. Porter, W. Charman, 2010, Pharmaceutical Research.

Lymphatic Transport of Methylnortestosterone Undecanoate (MU) and the Bioavailability of Methylnortestosterone Are Highly Sensitive to the Mass of Coadministered Lipid after Oral Administration of MU

Christopher J H Porter, Karen L White, G. Edwards, 2009, Journal of Pharmacology and Experimental Therapeutics.

Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs

Christopher J. H. Porter, David M. Shackleford, G. Edwards, 2003, Pharmaceutical Research.

Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.

C. Porter, S. Charman, W. Charman, 1996, Journal of pharmaceutical sciences.

Lipid-Based Formulations and Drug Supersaturation: Harnessing the Unique Benefits of the Lipid Digestion/Absorption Pathway

C. Pouton, C. Porter, H. Williams, 2013, Pharmaceutical Research.

Uptake of drugs into the intestinal lymphatics after oral administration

C. Porter, W. Charman, Christopher J.H. Porter, 1997 .

A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep

Victoria M Mcleod, C. Porter, P. Enkhbaatar, 2015, Pharmaceutical Research.

Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration

J. Li, R. Nation, C. Porter, 2014, Antimicrobial Agents and Chemotherapy.

Inhalational Administration Patients: Targeting Advantage of Methanesulfonate in Cystic Fibrosis of Inhaled and Intravenous Colistin Pulmonary and Systemic Pharmacokinetics

Jian Li, C. Porter, John W. Wilson, 2014 .

Tissue uptake of DDT is independent of chylomicron metabolism

P. Tso, R. Jandacek, C. Porter, 2006, Archives of Toxicology.

Digestion of phospholipids after secretion of bile into the duodenum changes the phase behaviour of bile components and alters solubilisation capacity of bile salt-lipid mixed micelles

Woldeamanuel A. Birru, Dallas B. Warren, C. Pouton, 2020 .

Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids.

Woldeamanuel A. Birru, Dallas B. Warren, C. Pouton, 2017, Molecular pharmaceutics.

An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine

Christopher J. H. Porter, C. Porter, W. Charman, 2002, AAPS PharmSci.

Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.

David M. Shackleford, C. Pouton, C. Porter, 2018, Molecular pharmaceutics.

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

S. Lewin, C. Sobey, P. King, 2017, Nature Communications.

Animal models for the study of intestinal lymphatic drug transport.

G. Edwards, C. Porter, W. Charman, 2001, Advanced drug delivery reviews.

50years of oral lipid-based formulations: Provenance, progress and future perspectives.

Christel A. S. Bergström, Hywel D Williams, Christopher J H Porter, 2016, Advanced drug delivery reviews.

In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.

Dallas B. Warren, Hywel D Williams, Christopher J H Porter, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations. 5. Lipolysis of Representative Formulations by Gastric Lipase

Anette Müllertz, Vincent Jannin, Christopher J. H. Porter, 2014, Pharmaceutical Research.

Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 6: Effects of Varying Pancreatin and Calcium Levels

A. Müllertz, C. Pouton, C. Porter, 2014, The AAPS Journal.

Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.

Christopher J H Porter, Natalie L Trevaskis, C. Porter, 2012, Journal of pharmaceutical sciences.

A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.

G. Edwards, R. Prankerd, C. Porter, 2002, Journal of pharmaceutical sciences.

Characterization of the drug binding specificity of rat liver fatty acid binding protein.

T. Velkov, C. Porter, M. Scanlon, 2008, Journal of medicinal chemistry.

An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli.

T. Velkov, R. Prankerd, C. Porter, 2005, Protein expression and purification.

The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport.

C. Porter, N. Trevaskis, Luojuan Hu, 2015, Journal of visualized experiments : JoVE.

Probing the fibrate binding specificity of rat liver fatty acid binding protein.

J. Wielens, T. Velkov, D. Chalmers, 2009, Journal of medicinal chemistry.

Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.

Jerome Wielens, Christopher J H Porter, Martin J Scanlon, 2014, ACS chemical biology.

Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats.

B. Boyd, C. Porter, Kathy Wai Yu Lee, 2013, Journal of pharmaceutical sciences.

Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins.

C. Porter, W. Charman, M. Mcintosh, 2004, Journal of Controlled Release.

Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers.

Christopher J. H. Porter, C. Porter, Lisa M. Kaminskas, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.

G. Edwards, C. Porter, W. Charman, 1998, Journal of pharmaceutical sciences.

Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacylglycerols

G. Edwards, H. Kristensen, A. Müllertz, 2006 .

Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide

C. Pouton, P. Thompson, C. Porter, 2021, Pharmaceutical Research.

PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

Christopher J H Porter, Lisa M Kaminskas, David B Ascher, 2013, Journal of controlled release : official journal of the Controlled Release Society.

A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations

C. Pouton, C. Porter, H. Williams, 2016, Pharmaceutical Research.

Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion.

Dallas B. Warren, Hywel D Williams, Christopher J H Porter, 2014, Journal of pharmaceutical sciences.

Lipid-Based Formulations and Drug Supersaturation: Harnessing the Unique Benefits of the Lipid Digestion/Absorption Pathway

Christopher J. H. Porter, Colin W. Pouton, C. Pouton, 2013, Pharmaceutical Research.

Microspheres for targeting drugs to specific body sites

Susan E. Dunn, M. Davies, S. Moghimi, 1993 .

Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome

Brian L. Schmidt, Rocco Latorre, Christopher J. H. Porter, 2018, Proceedings of the National Academy of Sciences.

Dietary docosahexaenoic acid supplementation enhances expression of fatty acid‐binding protein 5 at the blood–brain barrier and brain docosahexaenoic acid levels

P. Marriott, C. Porter, M. Scanlon, 2018, Journal of neurochemistry.

Examination of the impact of a range of Pluronic surfactants on the in‐vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone

B. Boyd, C. Porter, W. Charman, 2006, The Journal of pharmacy and pharmacology.

Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration.

Ben J. Boyd, Tracey Hanley, Christopher J. H. Porter, 2011, Journal of controlled release : official journal of the Controlled Release Society.

PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.

D. Ascher, Victoria M Mcleod, C. Porter, 2015, Molecular pharmaceutics.

Lipid-based systems for the enhanced delivery of poorly water soluble drugs.

Christopher J H Porter, Panayiotis Constantinides, P. Constantinides, 2008, Advanced drug delivery reviews.

Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach.

Christopher J H Porter, Susan A Charman, C. Porter, 2007, Journal of pharmaceutical sciences.

Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration.

C. Nowell, C. Porter, Estelle J A Suys, 2021, Nanomedicine.

The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein*

J. Wielens, T. Velkov, C. Porter, 2005, Journal of Biological Chemistry.

Fatty acid binding proteins shape the cellular response to activation of the glucocorticoid receptor

R. Weaver, C. Porter, M. Scanlon, 2021, bioRxiv.

A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor alpha agonists.

R. Weaver, L. Vuillard, C. Porter, 2019 .

A ligand-induced structural change in fatty acid–binding protein 1 is associated with potentiation of peroxisome proliferator–activated receptor α agonists

R. Weaver, L. Vuillard, C. Porter, 2018, The Journal of Biological Chemistry.

Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor α in a Ligand-selective Manner*

T. Velkov, D. Jans, K. Wagstaff, 2015, The Journal of Biological Chemistry.

Preparation, crystallization and preliminary X-ray diffraction analysis of two intestinal fatty-acid binding proteins in the presence of 11-(dansylamino)undecanoic acid.

M. Parker, J. Wielens, Aisha Laguerre, 2011, Acta crystallographica. Section F, Structural biology and crystallization communications.

Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein

T. Velkov, C. Porter, M. Scanlon, 2009, Molecular and Cellular Biochemistry.

Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay.

T. Velkov, Aisha Laguerre, C. Porter, 2007, Chemistry & biology.

Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs.

C. Pouton, D. Chalmers, C. Porter, 2021, Journal of controlled release : official journal of the Controlled Release Society.

Lipid Absorption Triggers Drug Supersaturation at the Intestinal Unstirred Water Layer and Promotes Drug Absorption from Mixed Micelles

Christopher J. H. Porter, C. Porter, N. Trevaskis, 2013, Pharmaceutical Research.

Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier.

Patrick Augustijns, Hywel D Williams, Christopher J H Porter, 2012, Molecular pharmaceutics.

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

Pierangelo Geppetti, Christopher J. H. Porter, Zhijian Cai, 2017, Proceedings of the National Academy of Sciences.

Reduced blood‐brain barrier expression of fatty acid‐binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega‐3 fatty acid diets

P. Marriott, C. Porter, M. Scanlon, 2018, Journal of neurochemistry.

Subcutaneous administration of AZD0466, a dendrimer-based Bcl-2/Bcl-xL inhibitor increases lymphatic exposure and survival in B-cell lymphoma.

A. Johnston, C. Porter, L. Kingston, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.

Christopher J H Porter, Colin W Pouton, David K Chalmers, 2018, Molecular pharmaceutics.

The impact of conjugation position and linker chemistry on the lymphatic transport of a series of glyceride and phospholipid mimetic prodrugs.

C. Porter, N. Trevaskis, T. Quach, 2020, Journal of pharmaceutical sciences.

Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid.

Garima Sharma, C. Porter, N. Trevaskis, 2023, Molecular pharmaceutics.

Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure

C. Porter, H. Williams, H. Benameur, 2019, Pharmaceutics.

Permeability assessment of poorly water-soluble compounds under solubilizing conditions: the reciprocal permeability approach.

C. Porter, S. Charman, K. Katneni, 2006, Journal of pharmaceutical sciences.

Model systems for intestinal lymphatic transport studies.

C. Porter, W. Charman, 1996, Pharmaceutical biotechnology.

Profiling the Role of Deacylation-Reacylation in the Lymphatic Transport of a Triglyceride-Mimetic Prodrug

C. Porter, N. Trevaskis, T. Quach, 2015, Pharmaceutical Research.

Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods.

C. Pouton, C. Porter, N. Trevaskis, 2017, Molecular pharmaceutics.

Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.

D. Owen, B. Kelly, Victoria M Mcleod, 2011, Journal of controlled release : official journal of the Controlled Release Society.

PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.

Christopher J H Porter, Lisa M Kaminskas, D. Owen, 2013, Journal of controlled release : official journal of the Controlled Release Society.

The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.

B. Kelly, B. Boyd, G. Krippner, 2008, Molecular pharmaceutics.

The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol

C. Porter, S. Caliph, F. Faassen, 2014, The Journal of pharmacy and pharmacology.

A Simple Quantitative Approach for the Determination of Long and Medium Chain Lipids in Bio-relevant Matrices by High Performance Liquid Chromatography with Refractive Index Detection

B. Boyd, C. Porter, Kathy Wai Yu Lee, 2013, AAPS PharmSciTech.

Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations.

C. Porter, H. Williams, H. Benameur, 2021, International journal of pharmaceutics.

Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products.

B. Boyd, C. Porter, W. Charman, 2003, Journal of pharmaceutical sciences.

Dispositif de liberation de medicaments par le systeme lymphatique

C. Porter, W. Charman, 2002 .

Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations

Dallas B. Warren, C. Pouton, D. Chalmers, 2021, Pharmaceutical Research.

Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.

Ben J. Boyd, Christopher J. H. Porter, Carleen Cullinane, 2012, Molecular pharmaceutics.

Impact of physicochemical properties on dendrimer pharmacokinetics and biodistribution

C. Porter, O. Feeney, S. Caliph, 2016 .

Fatty Acid Binding Proteins Expressed at the Human Blood–Brain Barrier Bind Drugs in an Isoform-Specific Manner

C. Porter, M. Scanlon, J. Nicolazzo, 2015, Pharmaceutical Research.

Understanding the Challenge of Beyond-Rule-of-5 Compounds.

Christel A. S. Bergström, Christopher J H Porter, Christel A S Bergström, 2016, Advanced drug delivery reviews.

Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.

Ben J Boyd, Christopher J H Porter, Lisa M Kaminskas, 2006, Molecular pharmaceutics.

Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations

C. Porter, Tri-Hung Nguyen, Yusuke Tanaka, 2020, Pharmaceutical Research.

A. Müllertz, C. Pouton, C. Porter, 2013, Pharmaceutical Research.

Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistribution.

Johannes C. Brendel, K. Jolliffe, S. Perrier, 2018, Biomaterials.

Lipid Absorption Triggers Drug Supersaturation at the Intestinal Unstirred Water Layer and Promotes Drug Absorption from Mixed Micelles

C. Porter, N. Trevaskis, Yan Yan Yeap, 2013, Pharmaceutical Research.

Non-linear Increases in Danazol Exposure with Dose in Older vs. Younger Beagle Dogs: The Potential Role of Differences in Bile Salt Concentration, Thermodynamic Activity, and Formulation Digestion

G. Edwards, C. Pouton, C. Porter, 2014, Pharmaceutical Research.

Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion.

R. Miller, C. Porter, W. Charman, 2000, International journal of pharmaceutics.

The effect of poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres

S. Davis, C. Porter, L. Illum, 1991 .

A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes

S. Hill, S. Briddon, T. P. Davis, 2021, The Journal of biological chemistry.

AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT

Christopher J H Porter, Natalie L Trevaskis, C. Porter, 2006, Drug Metabolism and Disposition.

Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery.

A. Wise, F. Caruso, R. Shepherd, 2018, ACS applied materials & interfaces.

Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations. 5. Lipolysis of Representative Formulations by Gastric Lipase

A. Müllertz, C. Pouton, C. Porter, 2015, Pharmaceutical Research.

Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.

Christopher J H Porter, Natalie L Trevaskis, G. Edwards, 2017, Molecular pharmaceutics.

Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations

Christel A. S. Bergström, Christopher J H Porter, Christel A S Bergström, 2018, Molecular pharmaceutics.

Engineering Biocoatings To Prolong Drug Release from Supraparticles.

A. Wise, F. Caruso, Jiajing Zhou, 2019, Biomacromolecules.

Intra-articular Injection of a B Cell Depletion Antibody Enhances Local Exposure to the Joint-Draining Lymph Node in Mice with Collagen-Induced Arthritis.

C. Nowell, C. Porter, N. Trevaskis, 2023, Molecular pharmaceutics.

Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity.

Christopher J H Porter, Lisa M Kaminskas, David B Ascher, 2016, Molecular pharmaceutics.

Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations

Christel A. S. Bergström, C. Porter, Linda C Alskär, 2018, Molecular pharmaceutics.

A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport

P. Tso, C. Porter, W. Charman, 2013, Pharmaceutical Research.

Transport and absorption of drugs via the lymphatic system.

C. Porter, W. Charman, C J Porter, 2001, Advanced drug delivery reviews.

Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism

Christopher J. H. Porter, David M. Shackleford, G. Edwards, 2009, Pharmaceutical Research.

Oral lipid-based formulations: using preclinical data to dictate formulation strategies for poorly water-soluble drugs

C. Porter, W. Charman, 2007 .

Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistribution.

Johannes C. Brendel, K. Jolliffe, S. Perrier, 2018, Biomaterials.

Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery.

A. Wise, F. Caruso, R. Shepherd, 2018, ACS applied materials & interfaces.

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.

D. Owen, B. Kelly, Victoria M Mcleod, 2014, Journal of controlled release : official journal of the Controlled Release Society.

In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623.

G. Edwards, C. Porter, N. Trevaskis, 2014, European journal of pharmaceutics and biopharmaceutics.

50years of oral lipid-based formulations: Provenance, progress and future perspectives.

Christel A. S. Bergström, C. Pouton, C. Porter, 2016, Advanced drug delivery reviews.

Increased In Vivo Exposure of N-(4-Hydroxyphenyl) Retinamide (4-HPR) to Achieve Plasma Concentrations Effective against Dengue Virus

David M. Shackleford, D. Jans, K. Wagstaff, 2023, Pharmaceutics.

'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.

C. Pouton, C. Porter, H. Williams, 2014, Journal of controlled release : official journal of the Controlled Release Society.

An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.

C. Pouton, C. Porter, H. Williams, 2014, Molecular pharmaceutics.

Size and rigidity of cylindrical polymer brushes dictate long circulating properties in vivo.

F. Caruso, B. Boyd, C. Porter, 2015, ACS nano.

The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group.

Christine M. Madla, L. Marciani, D. V. van Riet-Nales, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The impact of P‐glycoprotein efflux on enterocyte residence time and enterocyte‐based metabolism of verapamil

C. Porter, W. Charman, Brendan Johnson, 2001, The Journal of pharmacy and pharmacology.

Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats.

D. Owen, B. Kelly, Victoria M Mcleod, 2018, Journal of pharmaceutical sciences.

The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug.

B. Boyd, C. Porter, Kathy Wai Yu Lee, 2013, Journal of pharmaceutical sciences.

Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug.

C. Porter, N. Trevaskis, T. Quach, 2016, Journal of pharmaceutical sciences.

Passive tumour targeting and extravasation of cylindrical polymer brushes in mouse xenografts.

C. Nowell, C. Porter, M. Müllner, 2016, Chemical communications.

The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol

C. Porter, S. Caliph, F. Faassen, 2014, The Journal of pharmacy and pharmacology.